INVASIVE CERVICAL-CANCER AFTER LASER VAPORIZATION FOR CERVICAL INTRAEPITHELIAL NEOPLASIA - A 10-YEAR EXPERIENCE

被引:3
作者
CULLIMORE, JE
ROLLASON, TP
LUESLEY, DM
WARD, K
WADDELL, C
JORDAN, JA
机构
[1] BIRMINGHAM & MIDLAND HOSP WOMEN,BIRMINGHAM B11 4HL,W MIDLANDS,ENGLAND
[2] UNIV BIRMINGHAM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND
[3] BIRMINGHAM MATERN HOSP,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND
关键词
D O I
10.1089/gyn.1990.6.103
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The treatment of cervical intraepithelial neoplasia by laser vaporization has been in progress at the Birmingham and Midland Hospital for Women since September 1977. In this interval, 3182 patients have been treated. Seven women have developed invasive cancer at intervals 4–34 months postlaser. The lesions diagnosed were stage Ia (3), Ib (1), IIb (1), IIIa (1), and IV (1). These case histories are presented. On retrospective assessment, there were contraindications to local destructive treatment in six of the seven cases. This series emphasizes the need for thorough evaluation of patients before embarking on local destructive treatments and emphasizes the need for careful follow-up of treated patients. (J GYNECOL SURG 6:103, 1990) © 1990, Mary Ann Liebert, Inc. All rights reserved.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 21 条
  • [1] ANDERSON M, 1985, GYNAECOLOGICAL LASER, P137
  • [2] BENEDET JL, 1985, OBSTET GYNECOL, V65, P557
  • [3] BOON ME, 1981, CANCER, V48, P768, DOI 10.1002/1097-0142(19810801)48:3<768::AID-CNCR2820480318>3.0.CO
  • [4] 2-L
  • [5] BURGHARDT E, 1973, MAJOR PROBLEMS OBSTE, V6, P283
  • [6] CULLIMORE JE, 1989, LANCET, V1, P561
  • [7] CAN RISK-FACTORS BE IDENTIFIED FOR FAILURE OF LASER TREATMENT TO THE CERVIX
    CULLIMORE, JE
    WOODMAN, CBJ
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1988, 95 (11): : 1206 - 1208
  • [8] CONTRIBUTION OF ENDOCERVICAL CURETTAGE IN EVALUATING ABNORMAL CERVICAL CYTOLOGY
    DRESCHER, CW
    PETERS, WA
    ROBERTS, JA
    [J]. OBSTETRICS AND GYNECOLOGY, 1983, 62 (03) : 343 - 347
  • [9] GLOOR E, 1986, CANCER-AM CANCER SOC, V58, P1272, DOI 10.1002/1097-0142(19860915)58:6<1272::AID-CNCR2820580616>3.0.CO
  • [10] 2-B